Analysts Predict 16% Upside For TMSL
ETF Analysis: The T. Rowe Price Small - Mid Cap ETF (TMSL) has an implied analyst target price of $38.49 per unit, indicating a potential upside of 16.11% from its current trading price of $33.15.
Stock Performance Insights: Notable underlying holdings such as Centessa Pharmaceuticals, Enersys, and Warrior Met Coal show significant upside potential according to analysts, raising questions about the validity of these targets amidst market conditions.
Trade with 70% Backtested Accuracy
Analyst Views on TMSL
No data
About the author
Breaking Down the Components: TMSL May Have a Value of $41
ETF Analysis: The T. Rowe Price Small - Mid Cap ETF (TMSL) has an implied analyst target price of $41.26, indicating a potential upside of 15.58% from its current trading price of $35.70.
Notable Holdings: Key underlying holdings with significant upside potential include Vera Therapeutics (VERA) with a target price of $62.54, Firefly Aerospace (FLY) at $52.00, and Belden Inc (BDC) at $141.60, all showing substantial expected increases from their recent prices.
Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets could lead to downgrades if they are based on outdated information.
Investor Research: Investors are encouraged to conduct further research to assess the validity of analyst targets in light of recent company and industry developments.
Explore the Details: TMSL Projected to Rise by 16%
ETF Target Price Analysis: The T. Rowe Price Small - Mid Cap ETF (TMSL) has an implied analyst target price of $40.49, indicating a potential upside of 15.64% from its current trading price of $35.01.
Notable Holdings with Upside: Key underlying holdings such as First Advantage Corp, Korn Ferry, and Rhythm Pharmaceuticals show significant upside potential, with target prices exceeding their recent trading prices by 32.01%, 18.91%, and 18.11%, respectively.
TMSL's Holdings Suggest a 14% Potential Increase
ETF Target Price Analysis: The T. Rowe Price Small - Mid Cap ETF (TMSL) has an implied analyst target price of $39.61, indicating a potential upside of 13.86% from its current trading price of $34.79.
Notable Holdings with Upside Potential: Key underlying holdings in TMSL include Celldex Therapeutics (CLDX), Avidity Biosciences (RNA), and Service Corp. International (SCI), each showing significant upside to their respective analyst target prices.
Analyst Target Comparisons: CLDX's average target is $55.69 (146.42% upside), RNA's is $67.00 (40.11% upside), and SCI's is $91.80 (15.10% upside) compared to their recent trading prices.
Investor Considerations: Questions arise regarding the validity of these analyst targets, including whether they are justified based on current market conditions or if they reflect outdated expectations.
The Implied Analyst 12-Month Target For TMSL
ETF Analysis: The T. Rowe Price Small - Mid Cap ETF (TMSL) has an implied analyst target price of $39.15, indicating a potential upside of 17.84% from its current trading price of $33.22.
Stock Performance Insights: Notable underlying holdings with significant upside include Alkermes plc (ALKS), monday.com Ltd (MNDY), and Skyward Specialty Insurance Group Inc (SKWD), each showing potential increases of 53.23%, 40.33%, and 26.20% respectively based on analyst targets.
Analysts Predict 16% Upside For TMSL
ETF Analysis: The T. Rowe Price Small - Mid Cap ETF (TMSL) has an implied analyst target price of $38.49 per unit, indicating a potential upside of 16.11% from its current trading price of $33.15.
Stock Performance Insights: Notable underlying holdings such as Centessa Pharmaceuticals, Enersys, and Warrior Met Coal show significant upside potential according to analysts, raising questions about the validity of these targets amidst market conditions.
We Did The Math TMSL Can Go To $38
ETF Analysis: The T. Rowe Price Small - Mid Cap ETF (TMSL) has an implied analyst target price of $37.77 per unit, indicating a potential upside of 17.08% from its current trading price of $32.27.
Stock Performance Insights: Notable underlying holdings such as Centessa Pharmaceuticals, Kymera Therapeutics, and Primoris Services show significant upside potential based on analyst target prices, raising questions about the validity and optimism of these targets in light of recent market developments.
Breaking Down the Components: TMSL May Have a Value of $41
ETF Analysis: The T. Rowe Price Small - Mid Cap ETF (TMSL) has an implied analyst target price of $41.26, indicating a potential upside of 15.58% from its current trading price of $35.70.
Notable Holdings: Key underlying holdings with significant upside potential include Vera Therapeutics (VERA) with a target price of $62.54, Firefly Aerospace (FLY) at $52.00, and Belden Inc (BDC) at $141.60, all showing substantial expected increases from their recent prices.
Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets could lead to downgrades if they are based on outdated information.
Investor Research: Investors are encouraged to conduct further research to assess the validity of analyst targets in light of recent company and industry developments.
Explore the Details: TMSL Projected to Rise by 16%
ETF Target Price Analysis: The T. Rowe Price Small - Mid Cap ETF (TMSL) has an implied analyst target price of $40.49, indicating a potential upside of 15.64% from its current trading price of $35.01.
Notable Holdings with Upside: Key underlying holdings such as First Advantage Corp, Korn Ferry, and Rhythm Pharmaceuticals show significant upside potential, with target prices exceeding their recent trading prices by 32.01%, 18.91%, and 18.11%, respectively.
TMSL's Holdings Suggest a 14% Potential Increase
ETF Target Price Analysis: The T. Rowe Price Small - Mid Cap ETF (TMSL) has an implied analyst target price of $39.61, indicating a potential upside of 13.86% from its current trading price of $34.79.
Notable Holdings with Upside Potential: Key underlying holdings in TMSL include Celldex Therapeutics (CLDX), Avidity Biosciences (RNA), and Service Corp. International (SCI), each showing significant upside to their respective analyst target prices.
Analyst Target Comparisons: CLDX's average target is $55.69 (146.42% upside), RNA's is $67.00 (40.11% upside), and SCI's is $91.80 (15.10% upside) compared to their recent trading prices.
Investor Considerations: Questions arise regarding the validity of these analyst targets, including whether they are justified based on current market conditions or if they reflect outdated expectations.
The Implied Analyst 12-Month Target For TMSL
ETF Analysis: The T. Rowe Price Small - Mid Cap ETF (TMSL) has an implied analyst target price of $39.15, indicating a potential upside of 17.84% from its current trading price of $33.22.
Stock Performance Insights: Notable underlying holdings with significant upside include Alkermes plc (ALKS), monday.com Ltd (MNDY), and Skyward Specialty Insurance Group Inc (SKWD), each showing potential increases of 53.23%, 40.33%, and 26.20% respectively based on analyst targets.
Analysts Predict 16% Upside For TMSL
ETF Analysis: The T. Rowe Price Small - Mid Cap ETF (TMSL) has an implied analyst target price of $38.49 per unit, indicating a potential upside of 16.11% from its current trading price of $33.15.
Stock Performance Insights: Notable underlying holdings such as Centessa Pharmaceuticals, Enersys, and Warrior Met Coal show significant upside potential according to analysts, raising questions about the validity of these targets amidst market conditions.
We Did The Math TMSL Can Go To $38
ETF Analysis: The T. Rowe Price Small - Mid Cap ETF (TMSL) has an implied analyst target price of $37.77 per unit, indicating a potential upside of 17.08% from its current trading price of $32.27.
Stock Performance Insights: Notable underlying holdings such as Centessa Pharmaceuticals, Kymera Therapeutics, and Primoris Services show significant upside potential based on analyst target prices, raising questions about the validity and optimism of these targets in light of recent market developments.
